Article Text

Download PDFPDF
Paris staging system for primary gastrointestinal lymphomas
  1. A Ruskoné-Fourmestraux1,
  2. B Dragosics2,
  3. A Morgner3,
  4. A Wotherspoon4,
  5. D de Jong5
  1. 1Hotel Dieu, Paris, France
  2. 2Gesundheitszentrum, Vienna, Austria
  3. 3Medical Department 1, Technical University Hospital, Dresden, Germany
  4. 4Royal Marsden Hospital, London, UK
  5. 5The Netherlands Cancer Institute, Amsterdam, the Netherlands, on behalf of the European Gastro-Intestinal Lymphoma Study Group (EGILS)
  1. Correspondence to:
    Dr D De Jong, Department of Pathology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Currently, much effort is put into the development of specific therapeutical approaches that are tailored to specific lymphoma entities. As a consequence, more specific information needs to be collected to support the choice of therapy. In gastric marginal zone B cell lymphoma of MALT-type, the need for specialised documentation of tumour extent in the organ wall has been stressed by the high predictive value for failure of response after Helicobacter pylori eradication of infiltration beyond the mucosa, a predictive parameter irrespective of the presence of the t(11;18) translocation.1–,5 With new techniques such as endosonography, this infiltration depth can be assessed with improving accuracy. However, the information cannot be translated into the current staging systems. …

View Full Text